[情報] US:ASXC 財報

1. 標題：ASXC 財報
2. 來源：SA/FUTU
3. 網址：https://bit.ly/3BEFxqk
4. 內文：

很久沒關心這貨了,看到大漲才發現他財報,順手貼一下.

(來源:SA)

Asensus Surgical EPS in-line, beats on revenue
Nov. 03, 2021 4:08 PM ETAsensus Surgical, Inc. (ASXC)
By: Pranav Ghumatkar, SA

Asensus Surgical (NYSE:ASXC):
Q3 Non-GAAP EPS of -$0.06 in-line;
GAAP EPS of -$0.07 misses by $0.01.

Revenue of $2.57M (+217.3% Y/Y) beats by $1.55M.

---------------------------------------------
(來源:FUTU)

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Asensus Surgical, Inc. (NYSE
American: ASXC), a medical device company that is digitizing the interface
between the surgeon and the patient to pioneer a new era of
Performance-Guided Surgery™, today announced its operating and financial
results for the third quarter 2021.

北卡羅來納州研究三角公園--(美國商業資訊)--醫療設備公司Ascount Surgical，Inc.(紐約證券交易所美國證券交易所代碼：ASXC)今天宣佈了其2021年第三季度的經營和財務業績。該公司正在將外科醫生和患者之間的界面數字化，以開創績效導向手術™的新時代。

Recent Highlights

最近的亮點

Record quarter for procedures performed using Senhance® Surgical Systems,
growing 47% over the prior year

Four Senhance Surgical Programs recently initiated, three in Japan and one inRussia

Received FDA 510(k) clearance for expanded capabilities of the Intelligent
Surgical UnitTM (ISUTM), including first-of-its-kind 3D measurement, digital
tagging, image enhancement, and enhanced camera control

Received FDA 510(k) clearance for 5 mm articulating instruments

Six Senhance programs initiated year to date

-使用SEnhance®外科系統進行手術的創紀錄季度，比上年增長47%
-最近啟動了四個SEnhance外科項目，三個在日本，一個在俄羅斯
-獲得FDA 510(K)批准，以擴大智能外科單元的功能TM(執行支助股TM)，包括首創的3D測量 、數字標記、圖像增強和增強的相機控制
-獲得FDA 510(K)許可，可用於5 mm鉸接式器械
-今年到目前為止啟動的六個SEnhance計劃

"We are very proud of our recent performance as we continued to make
significant progress towards our strategic focus areas despite the meaningfulchallenges we faced during the quarter as a result of the most recent COVID
spike which impacted all of our key geographies. We have seen a recent
acceleration of new system installations as well as strong system utilizationtrends, which we believe reinforces that there is strong demand in the marketfor an innovative surgical platform that brings new capabilities to the
operating room, and that surgeons who have adopted Senhance are finding its
unique combination of surgical intelligence and foundational laparoscopic
movements both compelling and advantageous for themselves and their
patients," said Anthony Fernando, President and CEO of Asensus Surgical. "As
we look to the balance of 2021 and into 2022, we plan to continue this
momentum to drive increased global adoption and advance the capabilities of
Senhance to deliver on the promise of Performance-Guided Surgery."

我們對我們最近的表現感到非常自豪，因為我們繼續在我們的戰略重點領域取得重大進展，儘管由於最近影響到我們所有關鍵地區的COVID激增，我們在本季度面臨着重大挑戰。我們最近看到了新系統安裝的加速以及系統利用率的強勁趨勢，我們相信這加強了市場對創新外科平臺的強勁需求，這種平臺可以為手術室帶來新的能力，採用SEnhance的外科醫生發現它將外科智能和基礎腹腔鏡運動的獨特結合對他們自己和他們的患者既有吸引力又有優勢。“阿斯普拉斯外科公司總裁兼首席執行官安東尼·費爾南多説。隨着我們展望
2021年和2022年的平衡，我們計劃繼續這一勢頭，以推動全球更多的採用，並提高
SEnhance的能力，以兑現性能指導手術的承諾。“

Commercial and Clinical Update

商業和臨牀最新進展

Procedure Volume Trends

程序量趨勢

During the third quarter of 2021, procedure volumes increased by over 47%
compared to the prior year quarter, primarily driven by growth in Europe and
the United States. Sequentially, compared to the second quarter of 2021,
procedure volumes increased by 5%. Over 1,500 procedures have been completed
year to date, bringing total Senhance procedures to over 5,500 globally.

2021年第三季度，與去年同期相比，程序量增長了47%以上，這主要是由歐洲和美國的增長推動的。

與2021年第二季度相比，程序量增加了5%。今年到目前為止，已經完成了1500多例手術，使全球SEnhance手術總數達到5500多例。

New Senhance Program Initiations

新的SEnhance計劃啟動

The Company recently announced four new Senhance Robotic Surgery Program
initiations. Three Japanese hospitals entered into agreements to lease a
Senhance Surgical System, bringing the total number of Senhance programs in
Japan to seven. The fourth program initiation was in Russia, following a
hospital's purchase of a Senhance Surgical System. This represents the first
Senhance Surgical System to be utilized in Russia.

該公司最近宣佈了四項新的SEnhance機器人手術計劃。三家日本醫院簽署了租賃SEnhance外科系統的協議，使SEnhance在日本的項目總數達到7個。第四個項目是在俄羅斯啟動的，此前一家醫院購買了SEnhance外科系統。這是第一個在俄羅斯使用的SEnhance外科系統。

Year to date, six new Senhance programs have been initiated. For the full
year 2021, the Company continues to expect to initiate 10 - 12 new Senhance
programs.

今年到目前為止，已經啟動了六個新的SEnhance計劃。2021年全年，公司預計將繼續啟動10-12個新的SEnhance計劃。

Expanded Global ISU Machine Vision Capabilities

擴展的全球ISU機器視覺功能

In September, the Company announced that it received 510(k) clearance from
the FDA for an expansion of machine vision capabilities on the previously
cleared Intelligent Surgical Unit (ISU). The ISU is utilized with the
Company's Senhance Surgical System which enables Digital Laparoscopy. The
initial features of the ISU enable machine vision-driven control of the
camera for a surgeon by responding to commands and recognizing certain
objects and locations in the surgical field, and allow a surgeon to change
the visualized field of view using the movement of their instruments. The
newest ISU features expand upon these capabilities and introduce more
advanced features including: 3D measurement, digital tagging, image
enhancement, and enhanced camera control based on real-time data from
anatomical structures while performing surgery. This will be the first time
any of these features will be clinically available in soft-tissue abdominal
surgery.

今年9月，該公司宣佈，它獲得了FDA的510(K)許可，用於擴展之前獲得許可的智能外科單元(ISU)的機器視覺能力。ISU與該公司的SEnhance外科系統一起使用，該系統可以實現數字腹腔鏡檢查。ISU的初始特徵使外科醫生能夠通過響應命令並識別外科領域中的特定對象和位置來實現機器視覺驅動的攝像機控制，並允許外科醫生使用其器械的移動來改變可視化視野。最新的ISU功能擴展了這些功能，並引入了更多高級功能，包括：3D測量、數字標記、圖像增強，以及在進行手術時基於來自解剖結構的實時數據的增強型相機控制。這將是這些特徵首次在軟組織腹部手術中臨牀應用。

Articulating Instrument Clearance

鉸接式儀表間隙

In July, the Company announced that it had received 510(k) clearance for 5 mmarticulating instruments, which offer better access to difficult-to-reach
areas of the anatomy.

今年7月，該公司宣佈，它已經獲得了5毫米鉸接式器械的510(K)許可，這些器械可以更好地進入解剖結構難以觸及的區域。

Third Quarter Financial Results

第三季度財務業績

For the three months ended September 30, 2021, the Company reported revenue
of $2.6 million as compared to revenue of $0.8 million in the three months
ended September 30, 2020. Revenue in the third quarter of 2021 included $1.4
million in Senhance system revenue, $0.8 million in instruments and
accessories, and $0.4 million in services.

在截至2021年9月30日的三個月裏，該公司公佈的收入為260萬美元，而截至2020年9月30日的三個月的收入為80萬美元。2021年第三季度的收入包括140萬美元的SEnhance系統收入，80萬美元的儀器和附件收入，以及40萬美元的服務收入。

For the three months ended September 30, 2021, total operating expenses were
$16.7 million, as compared to $14.6 million in the three months ended
September 30, 2020.

截至2021年9月30日的三個月，總運營費用為1670萬美元，而截至2020年9月30日的三個月為1460萬美元。

For the three months ended September 30, 2021, net loss was $16.1 million, or$0.07 per common share, as compared to a net loss of $15.1 million, or $0.15
per common share, in the three months ended September 30, 2020.

截至2021年9月30日的三個月，淨虧損為1610萬美元，或每股普通股虧損0.07美元，而截至2020年9月30日的三個月，淨虧損為1510萬美元，或每股普通股虧損0.15美元。

For the three months ended September 30, 2021, the adjusted net loss of $14.3million, or $0.06 per common share, as compared to an adjusted net loss of
$11.9 million, or $0.12 per common share in the three months ended September
30, 2020, after adjusting for the following charges: amortization of
intangible assets, change in fair value of contingent consideration, change
in fair value of warrant liabilities, and employee retention tax credit, all
of which are non-cash charges. Adjusted net loss is a non-GAAP financial
measure. See the reconciliation from GAAP to Non-GAAP Measures below.

在截至2021年9月30日的三個月中，調整後的淨虧損為1430萬美元，或每股普通股0.06美元，而在截至2020年9月30日的三個月中，調整後的淨虧損為1190萬美元，或每股普通股虧損0.12美元，扣除以下費用後：無形資產攤銷、或有對價的公允價值變化、認股權證負債的公允價值變化和員工留任税收抵免，所有這些費用都是非現金費用。調整後的淨虧損是一項非公認會計準則的財務衡量標準。見下面從公認會計準則到非公認會計準則的對賬。

Balance Sheet Updates

資產負債表更新

The Company had cash, cash equivalents, short-term and long-term investments,excluding restricted cash of approximately $147.9 million as of September 30,2021.

截至2021年9月30日，該公司擁有現金、現金等價物、短期和長期投資，不包括約1.479億美元的限制性現金。

--

主要是預期看起來往好的方向走才大漲 不然前幾天記得也是爛透了

其實我一直在看他 只是就沒關注消息面. 他一直在1.7上下游移

不要忘了去年他發過一篇很經典的:未來買不到25000以下的道瓊 當時各種被酸 XD